Video

Dr. Perry on Implications of WHO Tumor Classifications in Brain Cancer

Author(s):

Arie Perry, MD, chief of Neuropathology, University of California, San Francisco, discusses the potential implications of the new World Health Organization central nervous system tumor classifications.

Arie Perry, MD, chief of Neuropathology, University of California, San Francisco, discusses the potential implications of the new World Health Organization (WHO) central nervous system (CNS) tumor classifications.

Perry explains that the new classifications will likely not change the therapeutic approach significantly, but that the change could impact the overall prognosis. There is the possibility, he added, that if the classification system dramatically changes the expected survival for a patient with brain cancer that a treatment plan could be altered in order to compensate. For pediatric tumors, depending on the individual cancer, treatment could also be altered dramatically, in terms of less aggressive or more aggressive treatments based on expected long-term outcomes.

Lastly, the genetic aspect of brain cancer should also be taken into consideration, Perry notes. The classifications identify germline mutations, in pediatric cancer, that affect the patient's family, in terms of the identification of hereditary tumors. This may identify other family members who are at increased risk for developing cancer.

<<<

View more from the 2016 SNO Annual Meeting

Related Videos
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP